Alfonso L Sabater1, Hazem M Mousa2, Xavier Quinones1, Felipe Valenzuela1, Ronald Mauricio Sanchez Avila3, Gorka Orive4,5,6,7, Eduardo Anitua4,5, Jesús Merayo3, Victor L Perez8,9. 1. Department of Ophthalmology, Bascom Palmer Eye Institute, Ocular Surface Center, University of Miami Miller School of Medicine, Miami, USA. 2. Steven and Frances Foster Distinguished Chair in Ocular Immunology, Duke Eye Center for Ocular Immunology, Duke University School of Medicine, Durham, NC, 27705, USA. 3. Fernández-Vega University Institute, Ophthalmologic Research Foundation, University of Oviedo, Oviedo, Spain. 4. Foundation Eduardo Anitua, Victoria, Spain. 5. Biotechnology Institute (BTI), Victoria, Spain. 6. NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain. 7. Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain. 8. Department of Ophthalmology, Bascom Palmer Eye Institute, Ocular Surface Center, University of Miami Miller School of Medicine, Miami, USA. victor.perez.quinones@duke.edu. 9. Steven and Frances Foster Distinguished Chair in Ocular Immunology, Duke Eye Center for Ocular Immunology, Duke University School of Medicine, Durham, NC, 27705, USA. victor.perez.quinones@duke.edu.
Abstract
PURPOSE: To evaluate the safety and efficacy of the surgical use of autologous plasma rich in growth factors fibrin membrane (mPRGF) in improving corneal wound healing and regeneration in a variety of complex ocular surface defects. METHODS: Chart review on 15 eyes of 14 included patients undergoing ocular surface intervention using intraoperative mPRGF at the Bascom Palmer Eye Institute and at the Instituto Oftalmológico Fernández-Vega was performed. Patients were grouped based on type of intervention or condition (penetrating keratoplasty, superficial keratectomy, neurotrophic or persistent corneal ulcers, and corneal perforation). Patients were followed for an average of 11 ± 5 months. Main outcomes measured were mPRGF dissolving time, best-corrected visual acuity, and evidence of any persistent epithelial defects, rejections, or complications. RESULTS: All 15 eyes underwent successful placement of mPRGF. Average dissolving time for fibrin membrane was 21 ± 3 days. mPRGF resulted in total healing of the corneal defects in 13/15 (86.7%) of the treated eyes and partial healing in 2/15 (13.3%) eyes in which persistent epithelial defects were noted on follow-up. Visual acuity improvement was seen in 9/15 (60%) of the cases. CONCLUSION: The use of autologous mPRGF in the healing and regeneration of the ocular surface is a secure and efficacious surgical option. Our data demonstrate that PRGF fibrin membrane should be contemplated as an important tool to optimize ocular surface regeneration in complex cases.
PURPOSE: To evaluate the safety and efficacy of the surgical use of autologous plasma rich in growth factors fibrin membrane (mPRGF) in improving corneal wound healing and regeneration in a variety of complex ocular surface defects. METHODS: Chart review on 15 eyes of 14 included patients undergoing ocular surface intervention using intraoperative mPRGF at the Bascom Palmer Eye Institute and at the Instituto Oftalmológico Fernández-Vega was performed. Patients were grouped based on type of intervention or condition (penetrating keratoplasty, superficial keratectomy, neurotrophic or persistent corneal ulcers, and corneal perforation). Patients were followed for an average of 11 ± 5 months. Main outcomes measured were mPRGF dissolving time, best-corrected visual acuity, and evidence of any persistent epithelial defects, rejections, or complications. RESULTS: All 15 eyes underwent successful placement of mPRGF. Average dissolving time for fibrin membrane was 21 ± 3 days. mPRGF resulted in total healing of the corneal defects in 13/15 (86.7%) of the treated eyes and partial healing in 2/15 (13.3%) eyes in which persistent epithelial defects were noted on follow-up. Visual acuity improvement was seen in 9/15 (60%) of the cases. CONCLUSION: The use of autologous mPRGF in the healing and regeneration of the ocular surface is a secure and efficacious surgical option. Our data demonstrate that PRGF fibrin membrane should be contemplated as an important tool to optimize ocular surface regeneration in complex cases.
Authors: Eduardo Anitua; Francisco Muruzabal; María de la Fuente; Jesús Merayo; Juan Durán; Gorka Orive Journal: Curr Eye Res Date: 2016-02-01 Impact factor: 2.424
Authors: Scheffer C G Tseng; Edgar M Espana; Tetsuya Kawakita; Mario A Di Pascuale; Wei Li; Hua He; Tzong-Shyne Liu; Tae-Hee Cho; Ying-Ying Gao; Lung-Kun Yeh; Chia-Yang Liu Journal: Ocul Surf Date: 2004-07 Impact factor: 5.033